Quantinno Capital Management LP lifted its stake in shares of Avantor, Inc. (NYSE:AVTR – Free Report) by 187.4% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,169,147 shares of the company’s stock after acquiring an additional 762,288 shares during the period. Quantinno Capital Management LP owned 0.17% of Avantor worth $9,166,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. EverSource Wealth Advisors LLC increased its stake in Avantor by 119.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock valued at $29,000 after purchasing an additional 1,189 shares in the last quarter. Private Trust Co. NA raised its holdings in shares of Avantor by 46.2% during the fourth quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock valued at $32,000 after purchasing an additional 875 shares during the period. Strategic Wealth Investment Group LLC bought a new position in shares of Avantor during the 2nd quarter worth about $32,000. Los Angeles Capital Management LLC bought a new position in shares of Avantor during the 4th quarter worth about $32,000. Finally, Osaic Holdings Inc. grew its stake in shares of Avantor by 60.9% in the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock valued at $38,000 after buying an additional 1,064 shares during the period. 95.08% of the stock is owned by institutional investors.
Avantor Price Performance
Shares of NYSE AVTR opened at $13.65 on Wednesday. Avantor, Inc. has a fifty-two week low of $7.26 and a fifty-two week high of $15.93. The stock has a market cap of $9.24 billion, a price-to-earnings ratio of -16.26, a PEG ratio of 10.30 and a beta of 0.89. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.18 and a current ratio of 1.78. The firm’s 50-day simple moving average is $10.48 and its 200 day simple moving average is $9.45.
Analysts Set New Price Targets
A number of analysts recently commented on the company. Evercore set a $10.50 target price on Avantor in a research report on Monday, July 6th. Wall Street Zen raised Avantor from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Barclays boosted their price objective on Avantor from $7.00 to $8.00 and gave the company an “underweight” rating in a report on Wednesday, June 24th. Wells Fargo & Company upped their target price on Avantor from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Finally, Citigroup increased their target price on Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Avantor presently has an average rating of “Hold” and a consensus target price of $12.00.
Check Out Our Latest Analysis on Avantor
Insider Activity
In related news, Director Gregory T. Lucier bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were bought at an average price of $8.32 per share, with a total value of $83,200.00. Following the completion of the transaction, the director directly owned 60,000 shares in the company, valued at approximately $499,200. This represents a 20.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.28% of the stock is currently owned by insiders.
About Avantor
Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor’s offerings are organized across two primary segments.
Read More
- Five stocks we like better than Avantor
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
